



BONESUPPORT Business update Q4(2021)

February 17th, 2022

Emil Billbäck, CEO

Håkan Johansson, CFO

DISCLAIMER

This presentation, which includes all information and data on the following slides, any oral statements made when presenting these slides, and any other material distributed or statements made at, or in connection with, such presentation (the “Presentation”), relates to BONESUPPORT HOLDING AB (the “Company”) and is furnished to you solely for your information and may not be reproduced or redistributed, in whole or in part, to any other person. By attending the meeting where this Presentation is made, or by reading the Presentation, you agree to be bound by the following limitations.

The Presentation is private and confidential, has been furnished to you solely for your information and may not be reproduced, redistributed or disclosed in any way, in whole or in part, directly or indirectly, to any other person without the prior written consent of the Company.

No representation or warranty (expressed or implied) is made as to, and no reliance should be placed on, the fairness, accuracy or completeness of the information contained in the Presentation. Accordingly, none of the Company, or any of its principal shareholders or subsidiary undertakings or any of such person’s officers, employees or advisors, including Carnegie Investment Bank AB (publ) and ABG Sundal Collier AB (collectively “the Managers”), accepts any liability (in negligence or otherwise) for any loss whatsoever arising directly or indirectly from the use of this Presentation. The Managers are acting for the Company and is not acting as adviser to any recipient of this document and will not be responsible to any recipient of this document for providing the protections afforded, to its clients.

The Presentation includes industry and market data pertaining to the Company’s business and markets. Unless otherwise indicated, such information is based on the Company’s analysis of multiple sources and the information contained in the Presentation has not been independently verified. The information and opinions contained in this Presentation do not purport to be comprehensive, are provided as at the date of the document and are subject to change without notice. The Company is not under any obligation to update or keep current the information contained in the Presentation. Moreover, this Presentation contains various forward-looking statements that reflect management’s current views with respect to future events and financial and operational performance. The words “believe,” “expect,” “anticipate,” “intend,” “may,” “plan,” “estimate,” “should,” “could,” “aim,” “target,” “might,” or, in each case, their negative, or similar expressions identify certain of these forward-looking statements. Others can be identified from the context in which the statements are made. These forward-looking statements involve known and unknown risks, uncertainties and other factors, which are in some cases beyond the Company’s control and may cause actual results or performance to differ materially from those expressed or implied from such forward-looking statements. These risks include but are not limited to the Company’s ability to operate profitably, maintain its competitive position, the Company’s ability to promote and improve its reputation and the awareness of the brands in its portfolio, the Company’s ability to successfully operate its growth strategy, the impact of changes in pricing policies, political and regulatory developments in the markets in which the Company operates, and other risks. None of the Company, or any of its principal shareholders or subsidiary undertakings or any of such person’s officers, employees or advisors, including the Managers, makes any warranties or representations about the achievement or reasonableness of such forward-looking statements.

This Presentation does not constitute an offer or invitation to subscribe for, or purchase, any shares of the Company and neither this Presentation nor anything contained herein shall form the basis of, or be relied upon in connection with, any contract or commitment whatsoever. Should the Company pursue the contemplated public offering in Sweden and international private placements outside of Sweden, any such offers will only be made once a prospectus in relation to the offer is published or made available. Any acquisition of shares in the offering should be made solely on the basis of the information contained in such prospectus, and no reliance is to be placed on any representations other than those contained in such prospectus.


This Presentation is not directed to, or intended for distribution to or use by, any person or entity that is a citizen or resident or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation or which would require any registration or licensing within such jurisdiction. The securities mentioned herein have not been and will not be registered under the US Securities Act of 1933, as amended (the “Securities Act”) and may not be offered or sold in the United States absent registration under the Securities Act or an exemption from the registration requirement thereof. There will be no public offer of the securities referred to herein in the United States. The securities referred to herein have not been and will not be registered under the applicable securities laws of Canada, Australia or Japan and may not be offered or sold within Canada, Australia or Japan or to any national, resident or citizen of Canada, Australia or Japan. Neither this Presentation nor any copy of it may be taken or transmitted into the United States of America, its territories or possessions, into Australia, Canada or Japan or be distributed, directly or indirectly, in the United States of America, its territories or possessions or to any US person, as that term is defined under the Regulation S under the Securities Act, or to any securities analyst or other person in any of those jurisdictions. Any failure to comply with this restriction may constitute a violation of United States, Australian, Canadian or Japanese securities law. The distribution of this Presentation in other jurisdictions may be restricted by law and persons into whose possession this Presentation comes should inform themselves about, and observe, any such restrictions.

Some of the information set out in the Presentation is still in draft form and has not been verified. In particular, the financial information included in this Presentation has not been audited and is therefore subject to change. In general, the information set out in the Presentation is subject to updating, completion, revision, verification and amendment, and such information may change materially.

Certain financial and other numerical information presented in this Presentation have been subject to rounding adjustments for the purpose of making this Presentation more easily accessible for the reader. As a result, the figures in tables may not sum up to the stated totals.

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURE.

BONESUPPORT – Fourth quarter report 2021



Q4 2021:

- Net sales SEK 61.4m, growth: 15% versus Q4 2020, +21% in constant exchange rates
- EBIT: SEK -21.8 m (SEK -26.7 m)

Full year 2021

- Net sales SEK 212.9 m, growth: 18% versus FY 2020, +23% in constant exchange rates
 - FY sales growth in 2021 versus FY 2019: +44%
- EBIT: SEK -87.8 m (SEK -101,4 m)

- Return of regional restrictions and deferrals of non-acute surgeries as Omicron variant drove high incidence rates and new peak in number of hospitalized COVID patients
- Launch of cannula and guiding tube for use and application of CERAMENT in proximity to joints, with minimal invasive procedures

COVID-19 impact on market dynamics

- Autumn recovery in surgical volumes was disrupted as the Omicron-variant surged in late Nov/ Dec, again placing the health care systems in a state of postponing non-critical surgical procedures.
- CERAMENT sales is correlated to number of surgeries, in turn determined by pandemic impact
- Shortage of staff has added challenges to surgery volumes (in the U.S.; 450 000/3% of workforce in Health Care has left since Feb 2020 – Nov 2021)
- With opening of society/ reduction of restrictions, patient flow is on a steeper trajectory than capacity utilization, creating increasing backlog/queues.


United Kingdom, Elective care, National Health System (NHS) Million people in queue

Nov 2020	Jan 2021	Mar 2021	May 2021	July 2021	Sept 2021	Nov 2021
4.5	4.6	5.0	5.3	5.6	5.8	6.0

Ref: NHS statistics. Every second month displayed since Nov-20


- **NHS received additional £ 5,4 bn whereof £ 1,5 bn for elective procedure recovery**
- **“Build Back Better” – decision made to increase elective care activity in the NHS by 30 percent by 2024–2025, compared to pre-pandemic levels**

Sweden, number of surgeries per day



- **Normal production: 1010 surgeries/day**
- **Back log: 156 k surgeries (126 k surgeries in May 21)**

New all-time-high, despite strong Omicron impact at end of quarter 4



North America:

Strong sales growth with continuously increasing market penetration

Q4 2021

- Sales of SEK 34.8 m, reported growth of 22% over Q4 2020, +31% in constant exchange rates
- Regionally high hospitalizations, as result of Omicron-variant, has deferred non-critical procedures

After period end:

- Signed strategic distribution agreement with OrthoPediatrics

CERAMENT G registration in the U.S.

- “Interactive review” with FDA following September supplementary DeNovo material submission. Potential market access grant decision in Q1 2022.
- Control group data contains more than 200 patients (PMMA beads)

Other highlights:

- Further strengthened commercial infrastructure; recruitment in Northern California and Mid West, for a total of 12 Regional Managers
- Hybrid set up in Canada

EUROW

Market conditions again constrained as Omicron break-out impacts surgical capacity and hospital access

Q4 2021

- Sales of SEK 26.6 m, a growth of 8% vs Q4 2020, +9% in constant exchange rates
- Regionally high levels of COVID hospitalized patients.

Highlights


- Selected clinics have extended surgical procedures to weekends, in order to reduce the build up of backlog
- Additional funding (political response to pandemic created back log) starting to be visible in U.K. health system surgical capacity
- Validating publication (Aljawadi et al.) on bone remodelling with severe trauma cases

Strong radiologic validation of bone remodeling in extended Trauma publication

Aljawadi A, Naylor T et al. (January 05, 2022) Radiological Analysis of Gentamicin Eluting Synthetic Bone Graft Substitute Used in the Management of Patients With Traumatic Bone Voids. Cureus 14(1): e20969. DOI 10.7759/cureus.20969

- 51 patients, retrospective data collected from 2015-2021, patient mean age 42 yrs
- 81% of patients with open fracture (Gustillo-Andersen IIIB) and 19% with closed fracture.
- X-ray performed at 6-9 weeks, 3 months, 4-6 months and 12 months


Conclusion: “Cerament-G used as a void filler for patients with traumatic bone void has resulted **98% fracture union rate** with good signs of **radiological remodeling into a trabecular bone**”





Financial Review

Q4 2021 net sales SEK 61.4 m



- A 30 percent growth CER in NA despite influence from the pandemic. 22 percent reported growth
- A 9 percent growth CER in EUROW despite influence from the pandemic. 8 percent reported growth

North America

+22%
(+30% CER)
Net Sales
Q4-21


North America	2021				2020
SEK m	Q4-21	Q3-21	Q2-21	Q1-21	Q4-20
Net Sales	34.8	32.7	29.1	25.1	28.6
Gross profit	32.7	30.6	27.1	23.3	27.2
Gross margin	94%	94%	93%	93%	95%
Contribution	3.7	1.3	-0.3	-2.0	0.1

EUROW


+8%
(+9% CER)
Net Sales
Q4-21

EUROW	2021				2020
SEK m	Q4-21	Q3-21	Q2-21	Q1-21	Q4-20
Net Sales	26.6	22.2	22.7	19.7	24.5
Gross profit	22.1	18.3	19.2	16.4	20.6
Gross margin	83%	82%	85%	83%	84%
Contribution	5.0	2.4	3.0	2.2	5.6

Net Sales and gross margin



Net Sales and gross margin



A 7.9 MSEK profit improvement before long-term incentive provisions

Key Figures	2021				2020			
	Q4	Q3	Q2	Q1	Q4	Q3	Q2	Q1
SEK m								
Net Sales	61.4	54.9	51.8	44.8	53.2	48.1	36.2	43.4
Gross Margin (%)	89.3	89.0	89.5	88.6	89.8	91.4	86.7	88.7
Operating Loss	-21.8	-13.3	-25.9	-19.7	-26.7	-19.2	-23.5	-29.2
Cash at period end	206.5	225.5	309.6	339.0	353.7	377.9	393.9	68.0

Q4 Insights

- Despite an intensified pandemic with Omicron, sales grew by 15 percent (21 percent in CER) compared to the fourth quarter of 2020.
- Gross margin remaining stable.
- Operating loss included expenses regarding long-term incentive programs amounting to SEK 4.8 million, compared with a cost of SEK 1.8 million in Q4 the previous year. The increased cost was mainly an effect from the first-time inclusion of the programs approved at the Annual General Meeting in May 2021.

Specific topics impacting expenses in Q4

Key Figures	2021				2020			
	Q4	Q3	Q2	Q1	Q4	Q3	Q2	Q1
Selling expenses (less commissions)	38.5	35.5	33.3	31.2	33.9	32.0	23.0	35.0
Sales Commissions	11.4	10.0	9.3	7.9	8.4	9.2	6.9	7.1
Research and Development expenses	14.4	11.3	15.8	12.3	16.5	11.7	14.0	15.8
Administrative expenses	14.8	⁽ⁱ⁾ 5.4	14.0	9.9	12.6	11.6	10.3	10.9
Total expenses	79.2	62.3	72.4	61.2	71.4	64.5	54.2	68.7

Q4 Insights


- Selling expenses increased with SEK 4.6 m compared with the same period last year. The higher cost level partially relates to the investments in hybrid markets, Italy and Spain. The period also contains significant demo kit replenishment and increase in freights and fees following the sales growth.
- R & D expenses reported below previous year as FORTIFY related costs have been phased out during the quarter.
- Administration remaining on a stable level excluding effects from the long-term incentive programs.

⁽ⁱ⁾ Administrative expenses in Q3 2021 included effects regarding incentive programs amounting to a reduced cost of SEK 2.4 million.



Clear Corporate Strategy
Driving Value Creation

BONESUPPORT journey ahead - Exciting near term milestones



Strategic execution and situational adaptation

- **Agile commercial adaptation, navigating through pandemic hurdles**
- **Strengthened commercial set up to benefit from post-pandemic dynamic:**
 - Solid and continuously growing customer base in US
 - Strategic partnership with OrthoPediatrics
 - + 2 Regional Managers (total 12)
 - Netherland converted to direct market
 - Foothold in South Africa, Middle East and Australia
 - Hybrid set up in Spain, Italy and Canada
- **CERAMENT G to the US market**
 - De Novo pathway – Interactive review throughout Q4 2021
 - Pursuit of broader label (trauma) once infection market access secured
- **Leveraging the value of clinical & health economic evidence**

Corporate target of an annual sales growth of 40%



Q&A